RWD154 Healthcare Resource Utilization (HCRU) and Costs of Poly(ADP-ribose) Polymerase Inhibitors (PARPi) as First-Line Maintenance (1LM) Treatment for Ovarian Cancer (OC)
Abstract
Authors
Laura Moore-Schiltz Joseph Tkacz Kathleen Wilson Jean A. Hurteau Jonathan Lim Alin Kalayjian John Hartman